ACAD ACADIA Pharmaceuticals Inc.
$27.83▲ +0.32%
Healthcare
Other
After hours
$27.55▼ -1.01%
Sep 11, 7:34 PM ET
Volume 1.17M
Avg Volume (10D) 1.31M
Key Metrics & Fundamentals
Market Cap
$4.80B
P/E Ratio
12.5
Div Yield
–%
52W Range
19.69 - 30.96
% vs 50 MA
1.26%
% vs 200 MA
13.35%
RSI-14
46.3
MACD Histogram
-0.3300
Beta (1Y vs SPY)
0.83
Free Cash Flow
$95.69M
Gross Rev
$307.96M
Gross Profit
$279.64M
EBITDA
$40.99M
COGS
$28.32M
Operating Exp
$241.81M
Operating Income
$37.84M
EBIT
$37.84M
Pretax Income
$46.47M
Net Income
$31.50M
EPS (Diluted)
0.18
Price & Volume History
Loading chart…
Recent News
Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?
Zacks · Sep 3, 2026 3:30 PM
Earnings To Watch: AcadeMedia AB (OSTO:ACAD) Q4 2026 -- GF Value Sees 6% Downside
GuruFocus.com · Aug 28, 2026 1:15 PM
Deutsche Bank Adjusts ACADIA Pharmaceuticals PT to $38 From $37, Maintains Buy Rating
MT Newswires · Aug 25, 2026 11:43 AM
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
Zacks · Aug 24, 2026 2:04 PM
ACADIA Pharmaceuticals Wins EU Approval for Rett Syndrome's Drug
MT Newswires · Aug 24, 2026 8:03 AM
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
Business Wire · Aug 24, 2026 7:01 AM
UBS Adjusts Price Target on ACADIA Pharmaceuticals to $49 From $45, Maintains Buy Rating
MT Newswires · Aug 17, 2026 1:39 PM
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data
MarketBeat · Aug 12, 2026 7:04 PM
Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 12, 2026 3:02 AM
Immunic appoints Elena Ridloff to board of directors
Proactive · Aug 10, 2026 8:36 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See ACAD's money flow as a full page
Social Sentiment
No Reddit posts found for ACAD.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.